Aegis Capital Corp. acted as Sole Bookrunner on a $8.4 Million Follow-On Offering for Medigus (NASDAQ: MDGS)
Aegis Capital Corp. acted as the Sole Bookrunner for a $8.4 million Follow-On Offering for Medigus (NASDAQ:MDGS). This funding is part of Medigus' efforts in medical-related devices and innovative technologies, including products for Gastroesophageal Reflux Disease (GERD) and biological gels designed for patient protection. Medigus also explores internet technologies, emphasizing investments in ad-tech and e-commerce solutions. The offering is expected to bolster Medigus' financial position and support ongoing projects across its subsidiaries.
- Successful $8.4 million follow-on offering to strengthen financial position.
- Active involvement in diverse medical and internet technology sectors, enhancing growth potential.
- Investment in innovative medical devices targeting GERD treatment.
- None.
NEW YORK, NY / ACCESSWIRE / January 13, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a
About Medigus
Medigus and its subsidiaries are focused on medical-related devices and products and on internet and other online-related technologies. Medical related activities include miniaturized imaging equipment through Scoutcam Inc. (formerly known as Intellisense Solutions Inc.), innovative surgical devices with direct visualization capabilities for the treatment of Gastroesophageal Reflux Disease (GERD) using Medigus Ultrasonic Surgical Endostapler, or MUSE, and biological gels to protect patients against biological threats and prevent intrusion of allergens and viruses through the upper airways and eye cavities through a stake and licensing arrangement with Polyrizon Ltd. Internet-related activities include ad-tech operations through a stake in Gix Internet Ltd., f/k/a Algomizer Ltd., or Gix, and its subsidiary, Linkury Ltd. Medigus also entered into agreements to acquire stakes in Eventer Technologies Ltd., an online event management and ticketing platform and SmartRepairPro, an e-commerce technology company.
About Aegis Capital Corp.
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services.
For more information about this offering or Investment Banking Services please email InvestmentBanking@aegiscap.com or call (212) 813-1010
This communication has been prepared by Aegis Capital Corporation for distribution to Aegis Capital Corporation's clientele. This communication is not intended for public dissemination and the recipient is prohibited from sharing this information. This communication has been prepared for institutional - accounts, as defined within FINRA Rule 4512(c), who (1) are capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities; and (2) will exercise independent judgment in evaluating the recommendations of any broker - dealer or its associated persons. This communication is not a product of Aegis Capital Corporation Research Department. Aegis Capital Corporation., Member FINRA, SIPC
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/624153/Aegis-Capital-Corp-acted-as-Sole-Bookrunner-on-a-84-Million-Follow-On-Offering-for-Medigus-NASDAQ-MDGS
FAQ
What is the amount raised in the Medigus follow-on offering?
Who acted as the bookrunner for Medigus' follow-on offering?
What areas does Medigus focus on?
What is the significance of the Medigus follow-on offering?
What medical condition does Medigus develop products for?
